Subscribe To
RVVTF / Revive Therapeutics touts publication of positive research data with Bucillamine in coronavirus
Content Topics
Revive
Therapeutics
Touts
Publication
Positive
Research
Data
Bucillamine
Coronavirus
Stock
RVVTF
RVVTF News
By Proactive Investors
July 28, 2023
Revive Therapeutics files patent application to treat chemical warfare agents exposure
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF). said it has filed a provisional patent application for the use of Bucillamine as a potential treatment more_horizontal
By Proactive Investors
July 6, 2023
Revive Therapeutics' study on safety and efficacy of Bucillamine to treat COVID 19 shows no statistical significance
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said the results of its Phase 3 clinical trial evaluating the safety and efficacy of oral Bucillamine i more_horizontal
By Reuters
July 6, 2023
Revive Therapeutics' experimental COVID treatment fails in late-stage study
Canada-based Revive Therapeutics said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study. more_horizontal
By Proactive Investors
May 30, 2023
Revive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDA
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has issued an update on the Phase 3 trial of its drug Bucillamine in patients with mild to moderate COV more_horizontal
By Proactive Investors
May 12, 2023
By Proactive Investors
May 12, 2023
Revive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next steps
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) saidĀ its Phase 3 clinical trial evaluating Bucillamine, an oral drug with anti-inflammatory and antivi more_horizontal
By Proactive Investors
May 2, 2023
Revive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trial
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has revealed that the independent Data and Safety Monitoring Board (DSMB) meeting for its Bucillamine P more_horizontal
By Proactive Investors
April 19, 2023
Revive Therapeutics to review next steps for Phase 3 Bucillamine study in COVID-19 patients
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has said it will review the next steps for the Phase 3 clinical trial of Bucillamine, its oral anti-inf more_horizontal